drugset / Trial / NCT04594135
Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies
Phase 1
Unknown
20 enrolled
iCell Gene Therapeutics
Peking University Shenzhen Hospital · collabiCAR Bio Therapeutics Ltd. · collab
NaSequentialOpen-labelTreatment
Summary
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of anti-CD5 CART cells in patients with relapsed and/or refractory T cell lymphoma or leukemia.
Timeline
- Start
- 2020-12-01
- Primary completion
- 2023-11-30
- Completion
- 2023-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | anti-CD5 CAR T cells | Cell therapy | 1e+06 cells/kg | — |
| Subject | anti-CD5 CAR T cells | Cell therapy | 5e+06 cells/kg | — |